Pediatric Langerhans Cell Histiocytosis: Hepatic Factors and Patient Outcomes

Eighty pediatric patients with liver involvement from a cohort of 453 children with Langerhans cell histiocytosis (LCH) were studied between 2007 and 2021. The dataset, authored by Seham Hassan and shared under CC-BY-4.0, analyzes structural and functional liver factors to identify prognostic determinants. Hepatic dysfunction was associated with a 5-year overall survival of 39.4%, compared to 92.6% for patients with preserved liver function.

Use Cases

• Predicting treatment failure based on the presence of hepatic dysfunction at diagnosis.
• Modeling 5-year overall survival using baseline biochemical factors like hypoalbuminemia.
• Assessing the prognostic value of early treatment response at week 6 for event-free survival.
• Comparing outcomes between distinct liver disease phenotypes (hepatomegaly vs. dysfunction).

Strengths

• Includes data from 453 pediatric patients treated over a 14-year period (2007-2021).
• Analysis is based on 80 cases with confirmed liver involvement, providing a focused cohort.
• Results include specific hazard ratios and odds ratios, such as an OR of 9.28 for initial treatment failure linked to hepatic dysfunction.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single treatment center in Egypt.

Provenance

Source

Children’s Cancer Hospital, Egypt

Collection Method

Retrospective clinical study evaluating patients using biochemical tests and ultrasonography.

Time Range

2007 to 2021

Freshness

Last updated 2026-05-29 04:53:26; freshness should be verified.

Geography

Egypt